RTS,S: the First Malaria Vaccine

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2022 Jan 4

PMID 34981788

Citations 45

Authors

Fidel Zavala

Affiliations

Soon will be listed here.

Citing Articles

iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA.

Yanik S, Venkatesh V, Gordy J, Alameh M, Meza J, Li Y NPJ Vaccines. 2025; 10(1):34.

PMID: 39971939 PMC: 11840135. DOI: 10.1038/s41541-025-01089-x.

Targeting T-Cell Activation for Malaria Immunotherapy: Scoping Review.

Gustifante B, Khairani S, Fauziah N, Riswari S, Berbudi A Pathogens. 2025; 14(1).

PMID: 39861032 PMC: 11768281. DOI: 10.3390/pathogens14010071.

Genetic variation of the circumsporozoite protein in parasite isolates from Homabay County in Kenya.

Maina M, Musundi S, Kuja J, Waweru H, Kiboi D, Kanoi B Front Parasitol. 2025; 3():1346017.

PMID: 39817167 PMC: 11732096. DOI: 10.3389/fpara.2024.1346017.

Frontiers in Parasitology Grand Challenge.

Loukas A Front Parasitol. 2025; 1():902098.

PMID: 39816472 PMC: 11731821. DOI: 10.3389/fpara.2022.902098.

The immunology of parasite infections: Grand challenges.

Donnelly S Front Parasitol. 2025; 1():1069205.

PMID: 39816470 PMC: 11732110. DOI: 10.3389/fpara.2022.1069205.

References

Raphemot R, Posfai D, Derbyshire E . Current therapies and future possibilities for drug development against liver-stage malaria. J Clin Invest. 2016; 126(6):2013-20. PMC: 4887158. DOI: 10.1172/JCI82981. View

Datoo M, Natama M, Some A, Traore O, Rouamba T, Bellamy D . Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. 2021; 397(10287):1809-1818. PMC: 8121760. DOI: 10.1016/S0140-6736(21)00943-0. View

Polhemus M, Remich S, Ogutu B, Waitumbi J, Otieno L, Apollo S . Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One. 2009; 4(7):e6465. PMC: 2714466. DOI: 10.1371/journal.pone.0006465. View

Stoute J, Slaoui M, Heppner D, Momin P, Kester K, Desmons P . A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 1997; 336(2):86-91. DOI: 10.1056/NEJM199701093360202. View

Oneko M, Steinhardt L, Yego R, Wiegand R, Swanson P, Kc N . Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat Med. 2021; 27(9):1636-1645. DOI: 10.1038/s41591-021-01470-y. View

Olotu A, Fegan G, Wambua J, Nyangweso G, Leach A, Lievens M . Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. N Engl J Med. 2016; 374(26):2519-29. PMC: 4962898. DOI: 10.1056/NEJMoa1515257. View

. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015; 386(9988):31-45. PMC: 5626001. DOI: 10.1016/S0140-6736(15)60721-8. View

Sidjanski S, Vanderberg J . Delayed migration of Plasmodium sporozoites from the mosquito bite site to the blood. Am J Trop Med Hyg. 1997; 57(4):426-9. DOI: 10.4269/ajtmh.1997.57.426. View

Nussenzweig R, Vanderberg J, MOST H, Orton C . Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature. 1967; 216(5111):160-2. DOI: 10.1038/216160a0. View

10.

White M, Verity R, Griffin J, Asante K, Owusu-Agyei S, Greenwood B . Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015; 15(12):1450-8. PMC: 4655306. DOI: 10.1016/S1473-3099(15)00239-X. View

11.

Gordon D, McGovern T, Krzych U, Cohen J, Schneider I, LACHANCE R . Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis. 1995; 171(6):1576-85. DOI: 10.1093/infdis/171.6.1576. View

12.

Sissoko M, Healy S, Katile A, Omaswa F, Zaidi I, Gabriel E . Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017; 17(5):498-509. PMC: 6803168. DOI: 10.1016/S1473-3099(17)30104-4. View

13.

NUSSENZWEIG V, Nussenzweig R . Circumsporozoite proteins of malaria parasites. Cell. 1985; 42(2):401-3. DOI: 10.1016/0092-8674(85)90093-5. View

14.

Wang L, Pereira L, Flores-Garcia Y, OConnor J, Flynn B, Schon A . A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver. Immunity. 2020; 53(4):733-744.e8. PMC: 7572793. DOI: 10.1016/j.immuni.2020.08.014. View

15.

Flores-Garcia Y, Wang L, Park M, Asady B, Idris A, Kisalu N . The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo. PLoS Pathog. 2021; 17(11):e1010042. PMC: 8601602. DOI: 10.1371/journal.ppat.1010042. View

16.

Kisalu N, Idris A, Weidle C, Flores-Garcia Y, Flynn B, Sack B . A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med. 2018; 24(4):408-416. PMC: 5893371. DOI: 10.1038/nm.4512. View

17.

Pholcharee T, Oyen D, Flores-Garcia Y, Gonzalez-Paez G, Han Z, Williams K . Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum. Nat Commun. 2021; 12(1):1063. PMC: 7887213. DOI: 10.1038/s41467-021-21221-4. View

18.

Bojang K, Milligan P, Pinder M, Vigneron L, Alloueche A, Kester K . Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001; 358(9297):1927-34. DOI: 10.1016/S0140-6736(01)06957-4. View